topotecan has been researched along with crizotinib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Hansel, TD; Infarinato, NR; Krytska, K; Makena, MR; Mossé, YP; Raman, P; Reynolds, CP; Ryles, HT; Sano, R; Song, MM | 1 |
| Gao, J; Li, X; Liu, Z; Teng, Y; Yin, P; Yu, P | 1 |
3 other study(ies) available for topotecan and crizotinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Crizotinib; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Mice, SCID; Mutation; Neuroblastoma; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Topotecan; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells.
Topics: Animals; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Topoisomerase Inhibitors; Topotecan | 2022 |